Kelun-Biotech has positioned 30+ oncology candidates for clinical advancement, establishing the Chinese firm as a significant competitor in the global antibody-drug conjugate race against Pfizer, Regeneron, and BioNTech.1 The pipeline concentration sets up a competitive approval cycle through 2027 that will likely reshape international biotech valuations in the oncology sector.
The ADC platform has become a focal point for pipeline investment across major pharmaceutical markets. These conjugates combine targeted antibody delivery with cytotoxic payloads, offering precision oncology approaches that command premium valuations. Kelun-Biotech's 30+ candidate pipeline represents aggressive capital deployment from China into this mechanism class, mirroring Western investment patterns.
Germany's BioNTech is advancing differentiated treatment approaches across lung cancer settings, including pumitamig, gotistobart, and a HER3-targeted ADC.2 In Japan, Regeneron's Dupixent—a fully human monoclonal antibody inhibiting IL-4 and IL-13 pathway signaling—received approval for bullous pemphigoid treatment, expanding the US company's footprint in Asia-Pacific markets.3
Smaller biotechs from emerging markets are also entering late-stage trials. Israel's Silexion Therapeutics received Ministry of Health approval for a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, targeting KRAS mutations present in over 90% of pancreatic cancers globally.4 The company's earlier Phase 2a trial of predecessor treatment Loder showed positive trends versus chemotherapy alone.5
The clustering of regulatory submissions in 2026-2027 creates both opportunity and risk for international investors. Companies reaching approval first in specific indications may capture market share across multiple jurisdictions before competitors launch. However, the crowded pipeline raises the bar for differentiation and could compress pricing power—particularly in price-sensitive markets outside the US—if multiple therapies target similar patient populations.
Pipeline velocity has become a critical valuation metric across global exchanges. Biotechs demonstrating clinical progress across multiple candidates simultaneously may command premiums over single-asset developers. The regulatory bottleneck ahead will test which platforms can execute at scale while navigating diverse approval standards in the US, EU, China, and Japan.
